NEW YORK—AbbVie Inc on Oct. 23 said its experimental rheumatoid arthritis (RA) treatment showed significant improvement in physical function, pain, and quality of life compared with the commonly prescribed generic drug methotrexate in a late-stage clinical trial.
The U.S. drugmaker hopes the drug, upadacitinib, can help replace lost revenue from its top-selling RA treatment Humira when it starts to face biosimilar competition in the United States in 2023.
